MSI-H

10 registered clinical trials studyying MSI-H — 5 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas NCT06346197	Centre Leon Berard	Phase 3
Recruiting	Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors NCT07001592	Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)	Phase 1
Recruiting	Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers NCT06580574	Peking University	Phase 2
Unknown	Registry Study in MSI/dMMR Solid Tumors NCT06004713	Peking University Cancer Hospital & Institute	—
Recruiting	A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant NCT05890742	Innovent Biologics (Suzhou) Co. Ltd.	Phase 3
Unknown	PD-1 Antibody Adjuvant Therapy for GC Patients With MSI-H After D2 Radical Surgery NCT05468138	Fudan University	Phase 2
Unknown	Immunotherapy Versus Chemotherapy as Adjuvant Therapy for Colon Cancer With MSI-H or POLE/ POLD1 Mutations NCT04969029	Tianjin Medical University Cancer Institute and Hospital	Phase 2
Recruiting	Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer NCT04636008	West China Hospital	Phase 1 / Phase 2
Completed	A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors NCT03775850	Evelo Biosciences, Inc.	Phase 1
Completed	Study of the CD40 Agonistic Monoclonal Antibody APX005M NCT02482168	Apexigen America, Inc.	Phase 1